Steve Edelman

1. BATTELINO, Tadej, BOSNYAK, Zsolt, DANNE, Thomas, MUKHERJEE, Bharati, EDELMAN, Steve, PILORGET, Valerie, CHOUDHARY, Pratik, RENARD, Eric, BERGENSTAL, Richard. InRange : Comparison of the second-generation basal insulin analogues Glargine 300 U/mL and Degludec 100 U/mL in persons with type 1 diabetes using continuous glucose monitoring. Diabetes therapy. 2020, vol. 11, iss. 4, str. 1017-1027. ISSN 1869-6961. https://link.springer.com/article/10.1007/s13300-020-00781-6, DOI: 10.1007/s13300-020-00781-6. [COBISS.SI-ID 7124396]

2. BATTELINO, Tadej, EDELMAN, Steve, NISHIMURA, Rimei, BERGENSTAL, Richard. Comparison of second-generation basal insulin analogs : a review of the evidence from continuous glucose monitoring. Diabetes technology & therapeutics. 2021, vol. 23, iss. 1, str. 20-30. ISSN 1520-9156. DOI: 10.1089/dia.2020.0180. [COBISS.SI-ID 97472771]

3. BATTELINO, Tadej, DANNE, Thomas, EDELMAN, Steve, CHOUDHARY, Pratik, RENARD, Eric, WESTERBACKA, Jukka, et al. Comparison of the basal insulin analogues Gla-300 and IDeg 100 using continuous glucose monitoring in people with type 1 diabetes: the InRange randomised controlled trial : invited lecture at the EASD 2022, 58th Annual Meeting, 19-23 September 2022. [COBISS.SI-ID 135521795]

4. BATTELINO, Tadej (avtor, korespondenčni avtor), DANNE, Thomas, EDELMAN, Steve, CHOUDHARY, Pratik, RENARD, Eric, WESTERBACKA, Jukka, MUKHERJEE, Bhaswati, PILORGET, Valerie, COUDERT, Mathieu, BERGENSTAL, Richard. Continuous glucose monitoring-based time-in-range usinginsulin glargine 300 units/ml versus insulin degludec100 units/ml in type 1 diabetes : the head-to-head randomizedcontrolled InRange trial. Diabetes, obesity & metabolism. 2023, vol. 25, iss. 2, [article no.] 14898, 545-555 str., ilustr. ISSN 1463-1326. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14898, Repozitorij Univerze v Ljubljani – RUL, DiRROS - Digitalni repozitorij raziskovalnih organizacij Slovenije, DOI: 10.1111/dom.14898. [COBISS.SI-ID 143145987]
projekt: P3-0343; financer: Slovenian Research Agency
projekt: DK108611; financer: National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Health)
projekt: Sofinancerji: Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, Indigo and Medtronic, AstraZeneca, Pfizer, Dxcom, Abbott and Roche, Abbott Diabetes Care, Sandoz, Novartis and Zealand Pharma

5. SCHNELL, Oliver, BATTELINO, Tadej, BERGENSTAL, Richard, BIRKENFELD, Andreas L., CERIELLO, Antonio, CHENG, Alice, DAVIES, Melanie C., EDELMAN, Steve, FORST, Thomas, GIORGINO, Francesco, et al. Report from the CVOT Summit 2022 : new cardiovascular, renal, and glycemic outcomes. Cardiovascular diabetology. 202ž3, vol. 22, str. 1-12, ilustr. ISSN 1475-2840. https://pubmed.ncbi.nlm.nih.gov/36927451/, DOI: 10.1186/s12933-023-01788-6. [COBISS.SI-ID 172319747]